Jodie Pang
Shenyang Pharmaceutical University(CN)Chongqing Normal University(CN)Qingdao University of Science and Technology(CN)Chongqing University(CN)Jinan University(CN)Taizhou Central Hospital(CN)First Hospital of Xi'an(CN)Nanjing University(CN)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Glioma Diagnosis and Treatment, Advanced Breast Cancer Therapies, Chronic Lymphocytic Leukemia Research, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer(2008)741 cited
- → Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition(2016)258 cited
- → GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway(2011)227 cited
- → Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer(2011)215 cited
- → Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity(2013)175 cited